Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x100px

Product › Details

Aldara®

	Next higher product group	imiquimod (INN)
	Status	1998-09-18 registration start

Record changed: 2023-07-10

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for immuno modulatory compound (IMO)

[1] Odyssey Therapeutics, Inc.. (12/5/23). "Press Release: Odyssey Therapeutics Announces $101 Million Series C Financing". Boston, MA....
[2] Tridek-One SAS. (9/15/22). "Press Release: Tridek-One Closes a €16 Million Financing Round to Develop First-in-Class Immune Checkpoint Agonists". Paris....
[3] Artax Biopharma, Inc.. (5/11/22). "Press Release: Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases". Cambridge, MA....
[4] Exscientia Ltd.. (8/18/21). "Press Release: Bristol Myers Squibb Exercises Option to Develop Exscientia’s AI-designed, Immune-modulating Drug Candidate". Oxford....
[5] Mestag Therapeutics Ltd.. (8/3/21). "Press Release: Mestag Therapeutics Extends Seed Financing to $45 Million and Welcomes New Investors Forbion, GV (formerly Google Ventures) and Northpond Ventures". Cambridge....
[6] Topas Therapeutics GmbH. (7/29/21). "Press Release: Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round". Hamburg....
[7] Mestag Therapeutics Ltd.. (4/20/21). "Press Release: Mestag Therapeutics Launches with Seed Financing of $11 Million to Develop Therapeutics Targeting Activated Fibroblast Populations across Inflammatory Disease and Cancer". Cambridge....
[8] Slate Bio, Inc.. (1/19/21). "Press Release: Slate Bio Launches with Seed Financing to Develop Next Generation IL-2 Therapies". Charlottesville, VA....
[9] Inflazome Ltd.. (9/21/20). "Press Release: Inflazome Announces Acquisition by Roche". Dublin & Cambridge....
[10] Inflazome Ltd.. (7/14/20). "Press Release: FDA Grants Orphan Drug Designation for Inflazome’s Inzomelid for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)". Dublin, Cambridge & Brisbane....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)